Dr. Christine Dahlke

Further involvements

• 25/09/2023

  14:50 – 15:00 8 Min. 2 Min.

  • Short Talk
  • S-2-3

  MVA-MERS-S vaccine candidate elicits long-lasting memory B cell response and highly potent cross-neutralizing antibodies against zoonotic merbecoviruses

   Immune Prevention and Therapy
• 25/09/2023

  • Poster
  • P-1-79

  Intracellular mRNA:miRNA profiling after rVSV-ZEBOV vaccination

   Immune Prevention and Therapy
• 26/09/2023

  • Poster
  • P-2-72

  Establishment of a multiplex digital PCR to detect MVA-based vaccines in human plasma

   Immune Prevention and Therapy
• 26/09/2023

  • Poster
  • P-2-104

  Mpox: evaluation of immune responses induced after infection versus vaccination

   Tropical and Emerging Infections
• 26/09/2023

  • Poster
  • P-2-105

  MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike induce differential S1- and S2-specific immune responses in humans

   Tropical and Emerging Infections
• 26/09/2023

  • Poster
  • P-1-78

  Dissecting humoral immune responses to the MVA-MERS-S vaccine candidate using a systems serology approach

   Immune Prevention and Therapy
• 26/09/2023

  15:30 – 15:40 8 Min. 2 Min.

  • Short Talk
  • S-6-4

  The vaccine candidate MVA-MERS-S against Middle East Respiratory Syndrome Coronavirus: safety and immunogenicity results from a randomized-controlled Phase Ib trial

   Tropical and Emerging Infections